cisplatin + gemcitabine hydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extrahepatic Bile Duct Cancer
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Trial Timeline
May 1, 2005 → —
NCT ID
NCT00262769About cisplatin + gemcitabine hydrochloride
cisplatin + gemcitabine hydrochloride is a phase 3 stage product being developed by Eli Lilly for Extrahepatic Bile Duct Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00262769. Target conditions include Extrahepatic Bile Duct Cancer, Gallbladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00262769 | Phase 3 | Completed |
Competing Products
4 competing products in Extrahepatic Bile Duct Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |